You are here

KRAS

Mirati and Novartis Pair Up to Evaluate Drug Combinations to Target KRAS G12C Mutations

Mirati and Novartis Pair Up to Evaluate Drug Combinations to Target KRAS G12C Mutations

BioSpace

Mirati Therapeutics

Flag link:

3 takeaways from cancer's biggest conference

3 takeaways from cancer's biggest conference

Biopharma Dive

accelerated approvals

Turning Point Therapeutics

Flag link:

3 Cancer Stocks Given a Lift by Amgen

3 Cancer Stocks Given a Lift by Amgen

Motley Fool

Mirati Therapeutics

Array Biopharma

Gilead Sciences

Flag link:

Did This Biotech Giant Just Find The Key To An 'Undruggable' Protein?

Did This Biotech Giant Just Find The Key To An 'Undruggable' Protein?

Investors Business Daily

Flag link:

Early cancer drug data give Amgen hope it's 'cracked KRAS code'

Early cancer drug data give Amgen hope it's 'cracked KRAS code'

Biopharma Dive

colorectal cancer

pancreatic cancer

Flag link:

Ionis Earns $28 Million from AstraZeneca for a New Drug to Treat Cancer

Ionis Earns $28 Million from AstraZeneca for a New Drug to Treat Cancer

Yahoo

Flag link: